Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2005

01-02-2005 | Poster presentation

Marked expression of IL-1 receptors in cell nuclei and muscle fiber membrane in muscle tissue of patients with idiopathic inflammatory myopathies

Authors: C Grundtman, S Salomonsson, C Dorph, J Burton, U Andersson, IE Lundberg

Published in: Arthritis Research & Therapy | Special Issue 1/2005

Login to get access

Excerpt

In chronic inflammatory diseases, IL-1 is known as an important proinflammatory cytokine inducing the expression of a variety of genes mediating the synthesis of several proteins, which can induce both acute and chronic inflammatory changes. Idiopathic inflammatory myopathies, such as polymyositis and dermatomyositis, are chronic autoimmune muscle disorders characterised by proximal muscle weakness and histopathological signs of patchy distribution of inflammatory cells in the skeletal muscle. Muscle tissue of patients with such myopathies has been shown to have an increased expression of IL-1α and IL-1β; however, the expression and pathophysiological role of IL-1 receptors in muscle tissue from such patients and healthy subjects has not yet been elucidated. …
Metadata
Title
Marked expression of IL-1 receptors in cell nuclei and muscle fiber membrane in muscle tissue of patients with idiopathic inflammatory myopathies
Authors
C Grundtman
S Salomonsson
C Dorph
J Burton
U Andersson
IE Lundberg
Publication date
01-02-2005
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 1/2005
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar1606

Other articles of this Special Issue 1/2005

Arthritis Research & Therapy 1/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine